Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SoluBest, a privately held, clinical stage developer of a novel solubilizing technology, has appointed Michael Sheckler as the company's new CEO.
Subscribe to our email newsletter
Mr Sheckler began his career with the Ross Division of Abbott Laboratories, selling nutritional and pharmaceutical products. During his time there, he served in a variety of sales roles. As a market research analyst, Mr Sheckler was responsible for the market assessment and product launch plans for several line extensions.
Prior to joining SoluBest, Mr Sheckler served as vice president of business development at Javelin Pharmaceuticals. During his tenure, he realized annual savings of $350 million through recognizing and negotiating a new contract manufacturing agreement and strengthened a successful $32 million fundraiser through serving an integral role in investor conferences and road shows.
Mr Sheckler graduated from Indiana University and obtained his MBA from The Fuqua School of Business at Duke University in Durham, North Carolina.
Ronnie Hershman, board chairman of SoluBest, said: “SoluBest has successfully advanced its technology in a critically important area of medicine. This promises to enhance patient outcomes through innovative and improved drug delivery. Now, with Michael Sheckler joining our team, we are confident that his added value will allow us to realize that promise in short order.”